ReviewACS pharmacology & translational science2024
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.
Review in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- No evidence for direct physical interaction of 5-HTbioRxiv : the preprint server for biology · 2026Article
- Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.ACS chemical neuroscience · 2026Review
- Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations.Research square · 2026Article
- Review
- Fentanyl, Methamphetamine and Polysubstance Use Differentially Affect Locomotor Sensitisation and Social Behaviour in Rats: Psychedelic Treatment Reverses Social Deficits.Addiction biology · 2026Article
- The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States.Journal of psychoactive drugs · 2025Article
- Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.ACS medicinal chemistry letters · 2025Article
- Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.ACS medicinal chemistry letters · 2025Article
- Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.ACS medicinal chemistry letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = -I) was first synthesized in 1973 in a structure-activity study to explore the effect of various aryl substituents on the then newly identified, and subsequently controlled, hallucinogenic agent 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM, or DOX where X = -CH
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.